KELIX bio, wholly owned by Mubadala Investment Company (Mubadala), said it completed the acquisition of DiabTec LLC, a subsidiary of Julphar.
The acquisition strengthens Mubadala’s portfolio of biologicals, establishes its role in biomanufacturing across the MENA region, and supports its efforts to advance the UAE’s life sciences sector through local manufacturing, the company said.
DiabTec’s facility includes 20,000-liter drug substance reactors and a separate cartridge fill-finish facility for drug products.
The state-of-the-art facility is built to EU/US FDA standards and is currently the only one in the GCC of this kind.
Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala’s UAE Investments Platform, said the strategic investment reflects the group’s commitment to responsible investing, addressing critical global healthcare challenges like the growing need for insulin analogues.
“Moreover, it strengthens Mubadala’s portfolio of biologicals, establishes our role in biomanufacturing across the MENA region, and advances the UAE’s life sciences sector through local manufacturing,” he said.
Sheikh Saqer Bin Humaid Al Qasimi, Chairman of the Board, Julphar, said the sale of this facility is a further step in Julphar’s strategy to divest non-core assets.
Hocine Sidi Said, CEO of KELIX bio, said with the rising number of diabetes patients globally, access to insulin analogues remains a challenge in many regions.
“To address this challenge, KELIX bio aims to improve access to critical treatments, ensuring that those in need can receive the care they require,” he said.
The move further consolidates Mubadala’s footprint in the life science ecosystem, and complements KELIX bio’s recent acquisition of four GlobalOne Healthcare Holding assets.
Follow us on
